Alfonso Berrocal Jaime, Ana Arance Fernández, V. E. Castellón Rubio, Luis de la Cruz-Merino, E. Espinosa Arranz, María González Cao, José Luis González Larriba, Iván Márquez Rodas, Ainara Soria, Salvador Martín Algarra
All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados